Novel 1,2,3-Triazole-functionalized pyrido[3',2':4,5]furo[3,2-d]pyrimidin- 4(3H)-one Derivatives: Synthesis, Anticancer Activity, CoMFA and CoMSIA Studies
作者:Balakishan Vadla、Sailu Betala
DOI:10.2174/1570178617666200319124017
日期:2020.12.8
azides under Sharpless reaction conditions, furnished triazole tagged pyrido [3',2':4,5]furo[3,2-d] pyrimidin-4(3H)-one derivatives. All the products 7a-p were screened against four human cancer cell lines, such as HeLa - Cervical cancer (CCL-2), COLO 205- Colon cancer (CCL-222), HepG2- Liver cancer (HB-8065), and MCF7 - Breast cancer (HTB-22) and one normal cell line (HEK 293). Compounds 7b, 7n, 7o and
由乙基呋喃[2,3-b]制备了一系列新型的三唑官能化吡啶基[3',2':4,5]呋喃[3,2-d]嘧啶-4(3H)-衍生物7a-p。吡啶-2-羧酸盐3与氨反应,得到呋喃并[2,3-b]吡啶-2-羧酰胺4。该化合物与原甲酸三乙酯TEOF反应,得到化合物5。化合物5在炔丙基化后进行反应在Sharpless反应条件下用取代的芳基叠氮化物提供三唑标记的吡啶并[3',2':4,5]呋喃[3,2-d]嘧啶-4(3H)-一衍生物。所有产品7a-p均针对四种人类癌细胞系进行了筛选,例如HeLa-宫颈癌(CCL-2),COLO 205-结肠癌(CCL-222),HepG2-肝癌(HB-8065)和MCF7 -乳腺癌(HTB-22)和一种正常细胞系(HEK 293)。化合物7b,7n,7o和7p,证实显示出有希望的抗癌活性,并且发现它们对正常细胞系无毒。使用CoMFA和CoMSIA对HeLa,COLO205,